TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug …
[Read more...] about Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
Akari Will Exclusively Partner with Industry Leader WuXi XDC For This Key IND-enabling Work Tampa, FL and London – December 23, 2025 – Akari …
Akari Therapeutics Announces Release of the Next CEO Corner Segment
Access the Akari CEO Corner here BOSTON and LONDON – November 25, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing …
[Read more...] about Akari Therapeutics Announces Release of the Next CEO Corner Segment
General Meeting of Shareholders (GM) to be held on December 15, 2025
NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 15, 2025 (CLICK TO VIEW AND DOWNLOAD) PROXY FORM (CLICK TO VIEW AND DOWNLOAD) SHARE …
[Read more...] about General Meeting of Shareholders (GM) to be held on December 15, 2025
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven …
